AEON Biopharma’s (AEON) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reissued their buy rating on shares of AEON Biopharma (NASDAQ:AEON) in a research note published on Monday, Benzinga reports. They currently have a $18.00 price target on the stock.

AEON Biopharma Trading Down 6.2 %

AEON stock opened at $1.66 on Monday. AEON Biopharma has a twelve month low of $1.38 and a twelve month high of $17.17. The business’s fifty day simple moving average is $8.48 and its two-hundred day simple moving average is $7.48.

AEON Biopharma (NASDAQ:AEON) last posted its quarterly earnings results on Friday, March 29th. The company reported ($0.71) EPS for the quarter. Analysts forecast that AEON Biopharma will post -1.18 EPS for the current year.

Hedge Funds Weigh In On AEON Biopharma

A hedge fund recently bought a new stake in AEON Biopharma stock. Atalaya Capital Management LP acquired a new position in AEON Biopharma, Inc. (NASDAQ:AEON) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 3,675,000 shares of the company’s stock, valued at approximately $19,827,000. AEON Biopharma makes up about 21.7% of Atalaya Capital Management LP’s investment portfolio, making the stock its biggest holding. Atalaya Capital Management LP owned approximately 41.28% of AEON Biopharma as of its most recent SEC filing. 22.78% of the stock is currently owned by hedge funds and other institutional investors.

AEON Biopharma Company Profile

AEON Biopharma, Inc, a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine.